Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis”), a clinical-stage biotechnology company specializing in the development of treatments that aim to slow down the degenerative processes linked to aging and improve the functional results of patients suffering from age-related illnesses, including respiratory failure in COVID-19 patients, today announced that it has received clearance from the Food and Drug Administration (FDA) to launch its SARA-31 study in the United States, the first phase 3 study ever launched in sarcopenia.